Considerations on the chemistry, manufacture and control requirements for conditional marketing authorization drugs in China

ZHAO Yifei; GENG Xin; XU Lihua; OU Ting; ZHANG Ning

doi:10.11665/j.issn.1000-5048.20210518

Journal of China Pharmaceutical University > 2021 > 52(5): 636-642. > DOI: 10.11665/j.issn.1000-5048.20210518

ZHAO Yifei, GENG Xin, XU Lihua, OU Ting, ZHANG Ning. Considerations on the chemistry, manufacture and control requirements for conditional marketing authorization drugs in China[J]. Journal of China Pharmaceutical University, 2021, 52(5): 636-642. DOI: 10.11665/j.issn.1000-5048.20210518

Citation:

PDF (1001 KB)

Considerations on the chemistry, manufacture and control requirements for conditional marketing authorization drugs in China

Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China

More Information

Received Date: April 02, 2021
Revised Date: September 05, 2021

Graphical Abstract

Abstract

Abstract

Drug Administration Law revised in 2019 proposed for the first time conditional marketing authorization at the legal level, marking the formal implementation of the conditional marketing authorization in China. This paper compares the regulations and technical requirements of conditional marketing authorization drugs in China with those in Europe and the United States, in an attempt to learn from the experience of chemistry, manufacture and control review of these drugs in Europe and the United States, and to discuss the pharmaceutical technical requirements of conditional marketing authorization drugs in China.
- chemical drugs,
- conditional marketing authorization,
- pharmacy,
- technological requirements

FullText(HTML)

References (13)

References

[1]	.Beijing： Chinese Medicine Science and Technology Publishing House，2017：80-81.
[2]	UnionEuropean.Commission Regulation （EC） No 507/2006［EB/OL］（2006-03-30）［2021-02-09］.https：//eur-lex.europa.eu/legal-content/EN/TXT/PDF/？uri=CELEX：32006R0507&qid=1614695279895&from=EN.
[3]	US Food & Drug Administraion.Code of Federal Regulations Title 21［EB/OL］（2020-04-01）［2021-03-06］.https：//www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm？CFRPart=314&showFR=1&subpartNode=21：5.0.1.1.4.8.
[4]	European Medicines Agency.Guideline on the scientific application and the practical arrangements necessary to implement Commission Regulation （EC） No 507/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation （EC） No 726/2004［EB/OL］（2016-02-25）［2021-03-12］.https：//www.ema.europa.eu/en/documents/scientific-guideline/guideline-scientific-application-practical-arrangements-necessary-implement-commission-regulation-ec/2006-conditional-marketing-authorisation-medicinal-products-human-use-falling_en.pdf.
[5]	Gov.UK.Conditional Marketing Authorisations，exceptional circumstances Marketing Authorisations and national scientific advice［EB/OL］（2020-12-31）［2021-02-25］.https：//www.gov.uk/guidance/conditional-marketing-authorisations-exceptional-circumstances-marketing-authorisations-and-national-scienti-fic-advice.
[6]	National Medical Products Administration（国家药品监督管理局）. Opinions of China Food and Drug Administration on resolving the backlog of drug registration applications and implementing priority review and approval（总局关于解决药品注册申请积压实行优先审评审批的意见）［EB/OL］（2016-02-26）［2020-12-18］.https：//www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20160226085101295.html.
[7]	National Laws and Regulations Database（国家法律法规数据库）. Drug administration law of the people''s republic of China（中华人民共和国药品管理法）［EB/OL］（2019-08-26）［2021-01-18］.https：//flk.npc.gov.cn/detail.html？ZmY4MDgwODE2ZjNjYmIzYzAxNmY0NjI0MmQ2MTI3ZWQ%3D.
[8]	National Medical Products Administration（国家药品监督管理局）. Drug registration management measures（药品注册管理办法）［EB/OL］（2020-03-30）［2021-02-09］.https：//www.nmpa.gov.cn/xxgk/fgwj/bmgzh/20200330180501220.html.
[9]	Center for Drug Evaluation，NMPA（国家药品监督管理局药品审评中心）.Guidance on conditional marketing authorisation of drugs（trial）［药品附条件批准上市技术指导原则（试行）］［EB/OL］（2020-11-19）［2020-12-10］.http：//www.cde.org.cn/news.do？method=largeInfo&id=e8e70cb03a94e5f2.
[10]	US Food & Drug Administraion.Guidance for industry expedited programs for serious conditions—drugs and biologics［EB/OL］（2014-05）［2021-02-21］.https：//www.fda.gov/media/86377/download.
[11]	US Food & Drug Administraion.Drugs@FDA［EB/OL］.https：//www.accessdata.fda.gov/scripts/cder/daf/.
[12]	Human medicine European public assessment report （EPAR）： Votubia［EB/OL］（2018-06-15）［2021-04-03］.https：//www.ema.europa.eu/en/medicines/human/EPAR/votubia.
[13]	Human medicine European public assessment report （EPAR）： Xalkori［EB/OL］（2012-07-19）［2021-04-06］.https：//www.ema.europa.eu/en/documents/assessment-report/xalkori-epar-public-assessment-report_en.pdf.

Cited By

Get Citation

PDF

XML

Article views (240) PDF downloads (662)

Turn off MathJax

Article Contents

Abstract

References

Considerations on the chemistry, manufacture and control requirements for conditional marketing authorization drugs in China

Abstract

References

Catalog

Export File

Citation

Format

Content